Of the many pressing challenges posed by COVID-19, a constant has been how to treat it — and how not to. Several drugs were said to potentially increase a person’s risk of poor outcomes following COVID-19 infection. Chief among these heavily blamed drugs were ACE inhibitors and statins, a belief based on animal studies that seemed to show a link. Concern also grew surrounding whether these drugs would put heart patients at risk, specifically.
Surgisphere created and conducted an observational study utilizing big data and AI to find out whether the use of these drugs increases the risk of COVID-19. The results showed that no, ACE inhibitors and statins are not associated with poor outcomes in patients who have COVID-19. This study was completed in collaboration with leaders at Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, Boston (Dr. Mandeep R. Mehra); Baylor College of Medicine and Department of Veterans Affairs, Houston (Dr. SreyRam Kuy); Christ Hospital, Cincinnati (Dr. Timothy D. Henry); and University of Utah, Salt Lake City (Dr. Amit N. Patel).
This finding has gained much attention in the healthcare community, in discussions surrounding COVID-19, and even in the wider media.
Recently, AIMed conducted an interview with Surgisphere’s CEO, Dr. Sapan Desai, to further discuss these findings and explore the observational study Surgisphere conducted. A corresponding article was also written that provides excellent background and context for the topic at hand.
To read the article and watch the video, see the following links.
Read the Article Here
Watch the Video Here